Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine

Key facts

Sponsor

Imaxio

Principal Investigator

Maryse Beder, MD

SIAAP

Enrollment

145 target

Eligibility

18-65 years · All sexes

Timeline

2017 – 2018

Study locations (2)

• SIAAP, Maisons-Laffitte, France
• Mairie de Paris, Paris, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Leptospirosis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07127718
  Preventive Strategies for Early and Late Complications of Leptospirosis
  National Kidney and Transplant Institute, Philippines
• RECRUITINGNANCT05436756
  Chronic Post-leptospirosis Manifestations in Reunion
  Centre Hospitalier Universitaire de la Réunion
• ACTIVE NOT RECRUITINGNANCT04034550
  Cohort of Hospitalized Patients Suspected of Leptospirosis
  Institut National de la Santé Et de la Recherche Médicale, France
• RECRUITINGNCT04288674
  Leptospirosis Registry - LeptoScope
  University of Cologne
• RECRUITINGNANCT05425524
  Leptospirosis Care Bundle Study
  Chulalongkorn University

See all trials for Leptospirosis →